Lipella Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Lipella Pharmaceuticals's earnings have been declining at an average annual rate of -41.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 35% per year.
Belangrijke informatie
-41.6%
Groei van de winst
-30.0%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | 35.0% |
| Rendement op eigen vermogen | -243.1% |
| Nettomarge | -816.7% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Lipella Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -4 | 2 | 0 |
| 31 Mar 24 | 0 | -5 | 2 | 0 |
| 31 Dec 23 | 0 | -5 | 2 | 0 |
| 30 Sep 23 | 0 | -4 | 2 | 0 |
| 30 Jun 23 | 0 | -4 | 1 | 0 |
| 31 Mar 23 | 0 | -3 | 1 | 0 |
| 31 Dec 22 | 0 | -3 | 0 | 0 |
| 30 Sep 22 | 0 | -3 | 0 | 0 |
| 30 Jun 22 | 0 | -2 | 0 | 0 |
| 31 Mar 22 | 0 | -2 | 0 | 0 |
| 31 Dec 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 1 | 0 | 0 | 0 |
| 31 Dec 19 | 1 | 0 | 0 | 0 |
Kwaliteitswinsten: LIPO is currently unprofitable.
Groeiende winstmarge: LIPO is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: LIPO is unprofitable, and losses have increased over the past 5 years at a rate of 41.6% per year.
Versnelling van de groei: Unable to compare LIPO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: LIPO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: LIPO has a negative Return on Equity (-243.13%), as it is currently unprofitable.